Abstract 22P
Background
The purpose of this study was to evaluate the characteristics and outcomes of early breast cancer patients who underwent skin-sparing mastectomy or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy without radiotherapy.
Methods
A total 104 patients with early breast cancer who underwent mastectomy with sentinel lymph node biopsy were identified in Korea Ansan University Hospital between 2007 and 2017. 85 total mastectomies (TM), 11 nipple areolar complex-sparing mastectomies (NSM), and 8 Skin-sparing mastectomiesm (SSM) were included. All these patients did not undergo adjuvant radiotherapy on chest wall or axillary area. We divided the patients into two groups, TM group and NSM/SSM group. We retrospectively collected clinitopathologic data for these patients. Locoregional recurrence rate, distant recurrence rate, overall recurrence free survival, and overall survival were determined. All statistical analysis was performed using SPSS 20.0 software (SPSS, Inc., Chicago, IL, USA).
Results
Median follow-up was 53 months. Fifty-five percentage of TM group patients received chemotherapy and 63.7 % of NSM/SSM patients received chemotherapy. Locoregional recurrence free survival was 95.3% vs. 78.9% in TM group and NSM/SSM group (p = 0.037). Locoregional failure rate was significantly high in NSM/SSM group than TM group. Distant recurrence free survival was 97.6% vs. 89.5% in TM group and NSM/SSM group (p = 0.128). Overall recurrence free survival was 92.9% vs. 78.9% in TM group and NSM/SSM group (p = 0.118). Overall survival was 98.8% and 94.7% in TM group and NSM/SSM group (p = 0.289). Total two deaths were observed in enrolled patients, one in TM group and another in NSM/SSM group. One death in TM group was unrelated to breast cancer and cause of death was complication from end-stage renal disease. One death in NSM/SSM group was related to breast cancer.
Conclusions
In conclusion, early breast cancer patients who underwent total mastectomy, skin-sparing mastectomy or nipple areolar complex-sparing mastectomy with sentinel lymph node biopsy had excellent outcomes without additional axillary surgery or radiotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
221P - Comparative analysis of first-line immune checkpoint inhibitor versus carboplatin-based chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma: A multicenter, retrospective real-world evidence
Presenter: Hsiang‐Lan Lai
Session: Poster display session
Resources:
Abstract
222P - Does tumor grade really improve the prognostic ability of the staging system for men with penile cancer: A SEER database analysis
Presenter: Ravi Kanodia
Session: Poster display session
Resources:
Abstract
223TiP - EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
Presenter: Daniel Petrylak
Session: Poster display session
Resources:
Abstract
230P - Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort
Presenter: Lingying Wu
Session: Poster display session
Resources:
Abstract
231P - Cost-effectiveness of olaparib vs routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
Presenter: David SP Tan
Session: Poster display session
Resources:
Abstract
233P - Incorporation of correlative studies in ovarian cancers in the era of precision medicine: Assessment of accountability and utility
Presenter: Nadia Hitchen
Session: Poster display session
Resources:
Abstract
234P - Implementation of mainstream BRCA testing in epithelial ovarian cancer in a tertiary centre
Presenter: Edbert Wong
Session: Poster display session
Resources:
Abstract
235P - The efficacy of radiation therapy in ovarian carcinoma: A propensity score analysis of a population-based study
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
236P - Front-line maintenance therapy for platinum-sensitive ovarian cancer: What’s next PARP inhibitors?
Presenter: Han Gong
Session: Poster display session
Resources:
Abstract
237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
Presenter: Saphalta Baghmar
Session: Poster display session
Resources:
Abstract